cross-linked hyaluronic acid
ApprovedSmall molecule
cross-linked hyaluronic acid is one of 40 small molecule programs targeting Bursitis. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
778 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1cross-linked hyaluronic acid
TTaipei Medical University
Approved
Ilaris
NovartisPreclinical
Toradol
RochePreclinical
Bayer Aspirin
BayerPreclinical
Platelet Rich Plasma
ZZagazig University
Preclinical
Enbrel
IImmunex
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Paracetamol
GSKPreclinical
Naproxen Sodium
BayerPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TTaipei Medical University